Skip to content

Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast

Wide Excision Alone for DCIS-Grades 1 and 2

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00165256
Enrollment
157
Registered
2005-09-14
Start date
1995-05-15
Completion date
2026-06-25
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ductal Carcinoma in Situ of the Breast

Keywords

Ductal carcinoma in situ, DCIS, wide excision

Brief summary

The purpose of this study is to determine if wide excision (surgical removal) alone is adequate treatment for small, grade 1 or 2 ductal carcinoma in situ (DCIS) of the breast.

Detailed description

* Patients with DCIS are usually treated with the combination of breast-conserving surgery and radiation therapy or breast-conserving surgery alone. The purpose of this study is to evaluate whether localized low- or intermediate-grade DCIS, diagnosed with modern mammography and careful pathologic evaluation, could be treated with wide excision alone (omission of radiation therapy) and result in acceptably low local recurrence rates. * Follow-up consists of physical examinations at least every 6 months by the surgeon or radiation oncologist. Mammograms of the affected breast will be obtained every 6 months for 5 years and then annually. Mammograms of the unaffected breast will be performed annually.

Interventions

OTHERObservation

Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue

Sponsors

Dana-Farber Cancer Institute
Lead SponsorOTHER
Brigham and Women's Hospital
CollaboratorOTHER
Massachusetts General Hospital
CollaboratorOTHER
Beth Israel Deaconess Medical Center
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients must have high quality mammogram including magnification views of the area containing suspicious calcifications. * A specimen radiograph is required. If the specimen radiograph does not assure removal of all suspicious microcalcifications, a post-operative mammogram showing removal of all suspicious calcifications is required. * The clinical extent of DCIS must be less than or equal to 2.5 cm. * Grade 1 or 2 DCIS; patients with lobular carcinoma-in-situ (LCIS) in addition to DCIS in the breast are eligible. Negative margins are not required on the LCIS. * Patients must undergo a wide excision. A re-excision after the initial biopsy might be needed. Complete resection of the area of DCIS with a histologic margin of at least 1 cm must be achieved. * Patients must be enrolled on this protocol within 3 months of the last surgical procedure.

Exclusion criteria

* Patients with invasive carcinoma including microinvasive disease * Carcinoma found in the sampled lymph nodes if axillary dissection is done * Patients with nipple discharge * Patients with adjuvant chemotherapy or Tamoxifen * Patients with a history of prior malignancies other than squamous or basal cell carcinoma of the skin, or carcinoma in situ of the cervix. * Patients with a history of ipsilateral or contralateral breast carcinoma or DCIS or simultaneous bilateral DCIS.

Design outcomes

Primary

MeasureTime frameDescription
To determine if patients with DCIS can be effectively treated with wide excision alone.TBD-survivorshipUsing information gathered from follow-up physical examinations and mammography to check for recurrence (DCIS or invasive carcinoma in the breast), DCIS patients treated with wide excision alone will be evaluated.

Secondary

MeasureTime frameDescription
To explore whether patients with grade 2 DCIS have a higher breast recurrence than patients with grade 1 DCIS.TBD-survivorshipUsing information gathered from follow-up physical examinations and mammography, the exploration of breast recurrences between grade 2 DCIS and grade 1 DCIS patients will be evaluated.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJulia Wong, MD

Dana-Farber Cancer Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 30, 2026